T ransthyretin cardiac amyloidosis (ATTR) results from misaggregation and myocardial deposition of wildtype (ATTRwt) or mutated (ATTRm) transthyretin (TTR) protein, increasing ventricular wall thickness, inducing heart failure (HF), and ultimately causing death.
1,2 Several single amino acid substitutions have been associated with ATTRm cardiac amyloidosis. Most notably, substitution of valine for isoleucine at codon 122 of the transthyretin (TTR) gene (V122I) (OMIM 176300) constitutes one of the most prevalent familial TTR amyloidoses in the United States. The V122I mutation is present in 3.43% of African American individuals 3 but generally absent in white individuals. 4 ATTRm V122I amyloidosis carries significant morbidity and mortality. 1, 5 Unfortunately, identification generally occurs after the development of symptoms, and a large number of cases are misdiagnosed or undiagnosed. 6, 7 Recent advances in pharmacologic therapy for ATTR have led to the development of targeted treatments with promising results in clinical trials. [8] [9] [10] Therefore, there is a pressing need for better testing to permit recognition of disease and to differentiate ATTR V122I amyloidosis from other causes of HF in at-risk patients. Currently, definitive diagnosis of ATTR cardiomyopathy requires Congo red staining of a cardiac biopsy specimen, biochemical or immunochemical demonstration of TTR as the pathologic protein, and TTR genotyping. Although cardiac magnetic resonance imaging can identify cardiac amyloidosis, 11 it does not provide conclusive information regarding amyloid disease type. Bone-avid technetium Tc 99m pyrophosphate and 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy (DPD) techniques are rapidly emerging as tools for cardiac ATTR identification 12 ;
however, these tests require experience to perform and interpret and, although increasing in use, have not yet achieved widespread adaptation. Normally, TTR circulates as a homotetramer complexed to retinol-binding protein 4 (RBP4), a 21-kDa protein integral to the transport of all-trans retinol (vitamin A). When bound to TTR, the RBP4-retinol complex stabilizes the TTR tetramer, inhibiting monomer dissociation and amyloid fibril formation. 13 In addition, RBP4 binding to the TTR tetramer prevents glomerular filtration of low-molecular-weight RBP4, effectively increasing its circulating levels. 14 It is widely held that mutations encode destabilizing amino acid replacements that induce TTR tetramer disassociation, resulting in fewer circulating RBP4-TTR complexes and increased urinary excretion of RBP4. 15 Alternatively, it is conceivable that decreased plasma concentration of RBP4 could result in lower TTR binding, thereby promoting tetramer destabilization. These observations suggest that RBP4 concentration may indicate the degree of TTR misfolding and therefore amyloid fibril formation. We sought to determine the utility of circulating RBP4 as a tool to identify ATTR V122I amyloidosis in a cohort of elderly African American patients with HF. We further aimed to develop a clinical prediction model for ATTR V122I amyloidosis based on clinical, echocardiographic, and electrocardiographic characteristics, along with RBP4 and other cardiac biomarkers.
Methods

Study Design
We conducted a case-control study of self-reported African American individuals with cardiomyopathy attributable to biopsy-proven ATTR V122I amyloidosis or nonamyloid causes. 2016 (using the same enrollment criteria as the initial part of the study) and identified an additional patient with ATTR V122I amyloidosis (total of 3 prospectively identified patients with ATTR V122I amyloidosis, 2 from the initial study period and 1 during the validation study recruitment). To enrich the validation cohort with additional ATTR V122I amyloidosis cases, we included 6 additional patients with biopsy-proven ATTR V122I amyloidosis seen at the Boston University Amyloidosis Center from July 15, 2014, through July 11, 2016. The total validation group was composed of 9 patients with ATTR V122I amyloidosis and 27 controls (eMaterial and eFigure 1 in the Supplement). The study was approved by the Boston University Medical Campus Institutional Review Board. All patients provided written consent before inclusion in the study, and data were deidentified. For the development of an assessment tool that maximized the diagnostic potential of noninvasive characteristics, multivariable logistic regression models were created using independent variables preselected as having a potentially useful diagnostic role based on a prior study 5 on ATTR V122I amyloidosis and on biological data. For 37 patients who had missing values in at least one of the predictor variables, multiple imputation was performed using predictive mean matching to fill in the missing values. 17 Least absolute shrinkage and selection operator (LASSO) regression was used to select the predictors of ATTR V122I amyloidosis that provided the optimal diagnostic value while minimizing overfitting. 18 The LASSO regression shrinkage parameter was determined using 10-fold cross-validation within each imputed data set. Details regarding the logistic regression analysis for the prediction rule for ATTR V122I amyloidosis can be found in the eMaterial in the Supplement. The goodness of fit of the LASSO regression prediction rule to the patient data was estimated by the HosmerLemeshow test 19 and by drawing calibration plots. To visualize the results of the model and its diagnostic potential, we plotted the ROC curve from the predicted probabilities from the rule and the ATTR V122I amyloidosis diagnosis. The prediction rule was subsequently tested on the validation cohort to assess its discrimination and goodness of fit. R statistical software, version 2.3.2 20 was used in all statistical analyses. Multiple imputation with predictive mean matching was performed using the mice R package, 17 whereas LASSO regression was performed with the glmnet package 18 and the ROC analysis with the pROC package. 16 Statistical significance was set at P < .05 for all comparisons. (Figure 1) . The 2 groups did not differ in the levels of hemoglobin A 1c , triglycerides, total cholesterol, or serum creatinine. Moreover, the ratio of RBP4 to TTR was not different between the 2 groups (mean [SD], 1.9 [0.5] vs 2.1 [0.7]; P = .30). In models that adjusted for age and sex, the differences in RBP4 and TTR remained statistically significant, whereas BNP and TnI were not found to be significantly different.
Serum Protein Quantification and Identification of TTR
Results
Baseline Patient Characteristics
Patients with ATTR V122I amyloidosis had higher myocardial wall thickness as measured by IVSD (mean [ 
RBP4 Concentration and ATTR V122I Cardiac Amyloidosis Identification
Because the RBP4 concentration was significantly lower in patients with ATTR V122I amyloidosis, we performed multivariable logistic regression analysis to assess whether this association was affected by confounding variables. The RBP4 concentration remained significantly different when controlling for age, sex, BMI, history of diabetes, creatinine level, nutritional status (albumin, modified BMI), hematocrit, cardiac biomarkers, and echocardiographic characteristics. Not surprisingly, RBP4 and TTR levels were highly correlated (Spearman ρ = 0.75, P < .001), and consequently, the association between RBP4 and ATTR V122I amyloidosis was not statistically significant when both RBP4 and TTR were included in the same logistic regression model. The ROC analysis identified RBP4 as a potentially sensitive diagnostic test for ATTR V122I amyloidosis cardiomyopathy (area under the curve [AUC] = 0.78; 95% CI, 0.67-0.88) (Figure 2A) . A threshold of 43 μg/mL maximized the Youden index, providing a sensitivity of 62% (95% CI, 47%-77%) and a specificity of 88% (95% CI, 76%-100%) for ATTR V122I amyloidosis. For screening, a cutoff value of 50 μg/mL achieved perfect sensitivity (100%; 95% CI, 100%-100%) but low specificity (38%; 95% CI, 23%-51%) for ATTR V122I amyloidosis. This threshold also yielded a negative predictive value of 100% in this total population with 33% prevalence of the disease. Of importance, 38% of the nonamyloid control cohort had RBP4 values above this threshold.
Diagnostic Model for ATTR V122I
To improve diagnostic performance, we developed a model for ATTR V122I identification by using several predetermined clinical factors, circulating biomarkers, and echocardiographic characteristics. In addition to RBP4 and TTR concentrations, we selected 6 variables available to clinicians by standard-of-care testing, including LVEF, IVSD, presence of grade 3 diastolic dysfunction, and mean limb lead QRS voltage, which significantly improved the final prediction rule. All other clinical characteristics (age, sex), circulating biomarkers (hemoglobin A 1c , triglycerides, total cholesterol, BNP, and TnI), and other electrocardiographic characteristics did not add significant diagnostic value and were excluded from the final model. Of note, our diagnostic model development is compliant with the TRIPOD statement for transparent reporting 22 (eTable in the Supplement).
The following prediction rule was developed as a result of this statistical modeling: ). Figure 2B shows the ROC curve for the prediction model. The ROC analysis identified the diagnostic model as an efficient discriminator of ATTR V122I with an AUC of 0.97 (95% CI, 0.93-1.00). Of note, the AUC of the model did not vary significantly among the different imputation data sets (range, 0.96-0.98). When applied to our original data set, the prediction rule did not demonstrate any statistical evidence of poor fit (Hosmer-Lemeshow statistic = 10.808, P = .21) (eFigure 2A in the Supplement). Of note, the median probability of controls not having ATTR V1221 based on the prediction model was 11.2% (interquartile range, 7.9%-15.6%), whereas the median probability of patients having ATTR V122I amyloidosis was 48.3% (interquartile range, 38.4%-68.9%).
Sensitivity Analysis
Recognizing the structural association of TTR and RBP4, we performed a sensitivity analysis using the same statistical method, excluding from the model TTR and the presence of grade 3 diastolic dysfunction because of its relative subjectivity (eMaterial in the Supplement). Figure 2D and E), whereas none of the models had any evidence of poor fit to the replication cohort (full model: HosmerLemeshow statistic = 3.52, P = .89; parsimonious model: Hosmer-Lemeshow statistic = 4.79, P = .78) (eFigure 3A and B in the Supplement). Of importance, one of the patients in the validation group was identified as being V122I TTR genotype positive but had no evidence of plasma cell dyscrasia or amyloid at technitium Tc 99m pyrophosphate scinitigraphy and was thus presumed to be genotype positive and amyloid phenotype negative. This individual's probability of ATTR V122I amyloidosis by our predictive models was low (10.4% by the full model and 11.6% by the parsimonious model), providing further confidence in the validity of our predictive model. Of note, in aggregate among the development and validation cohorts, 32 patients (97%) with ATTR V122 amyloidosis and 7 controls (9%) had predicted probability greater than 25% based on the full model, suggesting that a probability threshold of 25% using this model for any given patient could be used to trigger further diagnostic testing for ATTR V122I amyloidosis.
Discussion
In elderly African American individuals, ATTR V122I amyloidosis is an underrecognized cause of HF owing to the complexities of diagnosis and the prevalence of hypertensive heart disease in the target cohort. To facilitate identification and testing of a population at risk for ATTR V122I amyloidosis, we developed a novel mathematical prediction of disease based on LVEF, RBP4 concentration, IVSD, and mean limb lead QRS voltage, yielding a likelihood of ATTR V122I amyloidosis in African American individuals 60 years or older with HF. We submitted this model to rigorous statistical testing to confirm its quality of fit, demonstrating excellent discriminative capacity for ATTR V122I amyloidosis identification (AUC>0.9), which was subsequently confirmed in an independent validation cohort. The model may therefore be useful to guide clinicians as to whether a patient who fits the at-risk population will require further diagnostic testing, such as technetium Tc 99m pyrophosphate or 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy 12 or heart biopsy. Of importance, when considered individually, the specific measures used in the model proved to be insufficient to identify ATTR V122I amyloidosis. The demographic characteristics and cardiac measures among our study cohort were consistent with those in previous reports of patients with ATTR V122I amyloidosis. Restrictive filling (grade 3 diastolic dysfunction) was higher and mean limb lead QRS voltage was lower in patients with ATTR V122I amyloidosis. Of note, in our study, patients with ATTR V122I amyloidosis had higher TnI but lower BNP concentrations compared with patients with nonamyloid HF, but these results did not persist after controlling for age and sex. A previous study 1 found that BNP and TnI concentrations tend to be higher in patients with ATTR V122I amyloidosis, but differences in BNP were not found in another report. 5 Although most recruited control patients were identified during a clinically stable outpatient visit, it is possible that the cardiac biomarkers in our control population could have been skewed toward higher values because this information was collected from medical record review and would thereby be biased by the clinical indication for collection of these biomarkers in this group. Of interest, our results indicate that individuals with ATTR V122I amyloidosis had lower LVEF and greater wall thickness but did not differ in left ventricular mass index. This finding agrees ancy could reflect the fact that the ARIC study included carriers of the V122I mutation without limiting the population to patients with confirmed disease, skewing the echocardiographic indicators toward the general control population. Indeed, the median age of patients from the ARIC study at inclusion was 52 years, with the echocardiographic measurements being obtained at visit 5 (approximately 25 years later). A previous report 24 indicates that before the age of 65 years, there is no discernible effect of the V122I mutation in cardiac function. Similarly, in another cohort of elderly patients, the LVEF decreased by a mean of 3.2% in every 6-month interval of follow-up.
1
RBP4 was significantly associated with ATTR amyloidosis cardiomyopathy independent of potentially confounding variables. To our knowledge, this association has not been previously reported in the clinical setting, but in vitro disease models have found a potential role of RBP4 in stabilizing TTR and preventing misfolding. 25 We found that an RBP4 concentration greater than or equal to 50 μg/mL had 100% sensitivity (but modest specificity) and provided 100% negative predictive value in excluding ATTR V122I amyloidosis without the need for further testing (similar in the way that D-dimer concentration is used to exclude venous thromboembolism), suggesting a potential utility of RBP4 concentration as an initial screening test.
Limitations
Limitations of our study include the relatively small number of patients, although the number of patients with ATTR V122I amyloidosis in the context of worldwide prevalence estimates is reasonably sized. Because the prediction rule was developed in elderly African American individuals, we cannot generalize our findings to the general population of patients with HF, to younger populations, or to ATTRm from other amyloidogenic mutations. The results presented here are promising but preliminary. Although the prediction rule performance estimates remained excellent in a small replication cohort, external validation in a larger, independent patient population will be necessary before widespread clinical adaptation. Finally, although we definitively established the presence or absence of ATTR V122I amyloidosis in our study, a small possibility exists that our control group included a case of cardiac amyloidosis not attributable to ATTR V122I (ie, light chain amyloidosis or ATTRwt). The proportion of these individuals is expected to be small, if present at all, given that the known annual incidence of light chain cardiac amyloidosis is extremely low (approximately 1 case per 100 000 US population), 26 and in a large recent cohort of ATTRwt, more than 90% of patients with ATTRwt were white males and not African American. 27 Furthermore, even if a few of our controls had some other form of cardiac amyloid, this would not be expected to lead to an overestimate of our predictive model performance but would rather decrease the specificity (and subsequently the AUC) of our model by increasing the number of false-positive results.
Conclusions
We found a clinical prediction model based on RBP4 concentration and available standard-of-care clinical variables that has the potential to identify ATTR V122I amyloidosis and thereby trigger confirmatory testing. The test may have clinical utility as a first-line screening test for the disease in elderly African American individuals with HF, guiding clinical decision making. Furthermore, RBP4 concentration alone or in the context of this model may be useful to follow disease progression. Prospective validation of our prediction model in larger clinical cohorts is needed.
eMaterial. Supplemental Study Methods
Model development
For the development of a diagnostic assessment tool that maximizes the diagnostic potential of non-invasive parameters, multivariable logistic regression models were created with the following independent variables: age, gender, systolic blood pressure, body mass index, hematocrit, creatinine, beta natriuretic peptide, troponin, triglycerides, RBP4, TTR, electrocardiographic parameters (PR interval, QRS interval, QTc interval duration, mean limb lead QRS voltage and QRS voltage to LV mass ratio), and echocardiographic parameters (left ventricular ejection fraction, left ventricular mass index, interventricular septum diameter and presence of grade 3 diastolic dysfunction). These variables were preselected as having a potential diagnostic value based on biological plausibility and prior studies indicating their significant role in mutant ATTR. Gender, history of diabetes and presence of grade 3 diastolic dysfunction were modelled as categorical variables in logistic regression whereas all other parameters were modelled as continuous variables. Before model selection, multicollinearity was assessed by the variance inflation factor (VIF) with subsequent backwards elimination of variables with VIF>10. Selection of the best variables to be included in the final model was performed with the following process:
Deletion of cases with missing data may introduce bias and increases the variance (1). Therefore, before the analysis for model selection, in 37 patients that had at least one missing value for any of the aforementioned variables in our dataset, multiple (10-fold) imputation was performed by predictive mean matching (2). Of note, none of the patients had missing data on more than three variables. In fact, only 70 out of a total of 1875 (3.7%) individual values of the different variables were missing and imputed as described above. This led to the creation of 10 different datasets each consisting of the results of one imputation. As performing imputation to calculate values of the response variable could result in significant error and introduce bias, 4 patients whose TTR genotype was unknown were excluded from the analysis.
Least absolute shrinkage and selection operator (LASSO) regression was used to select the variables that would lead to the optimal diagnostic value. The LASSO regression method was preferred over traditional approaches like the Akaike information criterion as it tends to perform better in small datasets like ours and allows for the calculation of penalized regression coefficients that minimize error due to over-fitting and improve calibration (3, 4) . In each one of the 10 imputed datasets 10-fold cross validation was used to select the shrinkage parameter (lambda) that would minimize binomial deviance (5). The "one standard error" rule was used when selecting the best model. This approach acknowledges the fact that curves are calculated with error and errs on the side of parsimony (5). Regression coefficients for selected variables were calculated using the selected value of lambda. This method was used to calculate regression coefficients in all different datasets resulting from multiple imputation. Subsequently, the average value of the regression coefficients of the 10 different datasets for variables that were included in at least half of the resulting models was calculated and used in the final model. 
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